BrainsWay Ltd. (BWAY) - Form 20-F Summary
Business Context and Reporting Period
Company: BrainsWay Ltd.
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: BrainsWay is a global leader in non-invasive neurostimulation, utilizing its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform. The company holds FDA clearances for three indications: Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), and smoking addiction. The company operates primarily in the United States (85% of 2025 revenue) and Israel, with international distribution networks.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 (USD) | 2024 (USD) | Change |
|---|---|---|---|
| Total Revenue | $52.2 million | $41.0 million | +27.3% |
| Gross Profit | $39.4 million | $30.6 million | +29.1% |
| Operating Profit | $4.3 million | $1.4 million | +210% |
| Net Income | $7.6 million | $2.9 million | +162% |
| Cash & Equivalents | $67.7 million | $69.3 million | -2.3% |
| Operating Cash Flow | $17.5 million | $10.3 million | +70% |
| Accumulated Deficit | ($90.8 million) | ($98.4 million) | Reduced |
Revenue Composition (2025): Sales ($35.0M, 67%), Leases ($12.2M, 23%), Services ($5.0M, 10%).
Geographic Mix (2025): U.S. (85%), Other (15%).
Material Changes vs. Prior Period
- Profitability: The company achieved significant operating and net income growth, driven by a 27% revenue increase and improved operating leverage. Net income rose from $2.9M to $7.6M.
- Regulatory Milestones:
- November 2025: FDA cleared expanded labeling for adolescent MDD (ages 15-21).
- September 2025: FDA cleared an accelerated treatment protocol (SWIFT) for MDD.
- May 2024: FDA cleared expansion for late-life MDD (ages 69-86).
- Strategic Investments: Entered into a multi-phased investment agreement with Neurolief (up to $16M) and acquired minority stakes in several Management Service Organizations (MSOs) including Stella, Axis, and Tangient to expand access to care.
- Capital Structure: Consummated a private placement with Valor BrainsWay Holdings in Nov 2024 ($20M). Valor exercised warrants in Oct 2025 on a cashless basis, resulting in the issuance of 553,730 ADSs.
Guidance, Outlook, and Risks
Outlook: Management expects to continue investing in R&D for next-generation technology (Deep TMS 360/rotational field) and clinical trials for new indications (e.g., Alcohol Use Disorder). The company believes existing cash resources ($67.7M) are sufficient to fund operations in the foreseeable future.
Key Risks:
- Geopolitical Instability: Significant operations and manufacturing are located in Israel. Ongoing conflicts (Israel-Gaza, Israel-Hezbollah, US-Israel-Iran) pose risks to supply chains, workforce availability (reserve duty), and facility safety.
- Customer Concentration: A single large enterprise customer accounted for approximately 34% of 2025 revenues. Loss of this customer would materially impact results.
- Reimbursement: While MDD reimbursement is robust, coverage for OCD is emerging, and smoking addiction currently lacks third-party reimbursement, relying on cash-pay models.
- Intellectual Property: Received a letter from Magnus Medical Inc. alleging IP infringement regarding the accelerated TMS protocol; potential litigation cannot be ruled out.
- Supply Chain: Reliance on third-party suppliers for critical components (stimulators, capacitors) creates vulnerability to global disruptions and geopolitical shipping issues.
Investor Verification Checklist
- Customer Concentration: Verify the stability and contract terms of the single customer representing ~34% of revenue.
- Geopolitical Exposure: Assess the specific impact of ongoing Middle East conflicts on the company's Israeli manufacturing and workforce (reserve duty status).
- Reimbursement Trends: Monitor the expansion of insurance coverage for OCD and the potential for smoking addiction reimbursement.
- IP Litigation: Track the status of the Magnus Medical Inc. infringement claim regarding the accelerated protocol.
- Investment Milestones: Verify the achievement of milestones for the Neurolief and MSO investments to trigger additional funding obligations or equity conversions.